Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 6:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 484 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Background Treatment Clear all
Terminated Phase 3 Interventional Results available

Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis

NCT04181762
View directory record Official record
Conditions
Lupus Nephritis
Interventions
secukinumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
8
States / cities
Birmingham, Alabama • Fontana, California • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Sep 8, 2026, 6:01 PM EDT
Completed Phase 3 Interventional

TMC125-C206: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.

NCT00254046
View directory record Official record
Conditions
HIV
Interventions
TMC125, Placebo
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
18 Years and older
Enrollment
616 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
32
States / cities
Little Rock, Arkansas • Beverly Hills, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2014 · Synced Sep 8, 2026, 6:01 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV

NCT02016924
View directory record Official record
Conditions
Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Interventions
ATV, DRV, Cobicistat, BR, F/TAF, LPV/r, Third Unboosted Drug, Cobicistat TOS, F/TAF TOS
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
4 Weeks to 17 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
7
States / cities
Long Beach, California • Los Angeles, California • Aurora, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 8, 2026, 6:01 PM EDT
Completed Phase 3 Interventional Results available

Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME)

NCT04183335
View directory record Official record
Conditions
Neurodermatitis
Interventions
Dupilumab SAR231893, Placebo, Moisturizers, Low to medium potent topical corticosteroids, Topical calcineurin inhibitors
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
21
States / cities
Gilbert, Arizona • Fort Smith, Arkansas • Sacramento, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Sep 8, 2026, 6:01 PM EDT
Completed Not applicable Interventional

A Mind-body Intervention to Improve Body and/or Self Image

NCT02531997
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer, Uterine Cancer, Cervical Cancer
Interventions
Hypnotic Relaxation Therapy, Progressive Muscle Relaxation
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
21 Years and older · Female only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Sep 8, 2026, 6:01 PM EDT
Terminated Phase 2 Interventional Results available

Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)

NCT01946880
View directory record Official record
Conditions
Systemic Lupus Erythematosus, SLE
Interventions
Mycophenolate Mofetil, Hydroxychloroquine or Chloroquine, Prednisone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
19
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2020 · Synced Sep 8, 2026, 6:01 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pediatric Preventative Health Screenings - Obesity and Family-Centered Outcomes

NCT02850224
View directory record Official record
Conditions
Obesity, Overweight, Blood Pressure, Hypercholesteremia, Diabetes
Interventions
Motivational interviewing to elicit PCO in pediatrics
Behavioral
Lead sponsor
Henry Ford Health System
Other
Eligibility
2 Years to 18 Years
Enrollment
703 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Sep 8, 2026, 6:01 PM EDT
Active, not recruiting Phase 3 Interventional

Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)

NCT05771480
View directory record Official record
Conditions
Biliary Tract Cancer
Interventions
Durvalumab, Gemcitabine monotherapy, Gemcitabine + cisplatin, Gemcitabine + oxaliplatin, Gemcitabine + carboplatin, Gemcitabine + cisplatin + S-1, Gemcitabine + S-1, Gemcitabine + cisplatin + albumin-bound paclitaxel
Biological · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
4
States / cities
Mobile, Alabama • Orange, California • Washington D.C., District of Columbia + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 8, 2026, 6:01 PM EDT
Completed Not applicable Interventional Results available

Using Social Media to Decrease Healthcare Utilization for Pediatric Asthma

NCT05013788
View directory record Official record
Conditions
Asthma in Children
Interventions
Social Media Enhanced Education, Usual Asthma Education
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
3 Years to 17 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Sep 8, 2026, 6:01 PM EDT
Active, not recruiting Phase 3 Interventional

Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

NCT04493853
View directory record Official record
Conditions
Hormone-Sensitive Prostate Cancer
Interventions
Capivasertib, Placebo, Abiraterone Acetate
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Male only
Enrollment
1,012 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
33
States / cities
Tucson, Arizona • La Jolla, California • Orange, California + 29 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 8, 2026, 6:01 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care

NCT03371251
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
BOS161721, Placebo
Drug
Lead sponsor
Boston Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
17
States / cities
Anniston, Alabama • El Cajon, California • Los Alamitos, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2022 · Synced Sep 8, 2026, 6:01 PM EDT
Completed Not applicable Interventional

Active Choice in the EHR to Promote Statin Therapy

NCT03271931
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Active choice, Passive choice
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
23,066 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Sep 8, 2026, 6:01 PM EDT
Terminated Not applicable Interventional

A Breast Cancer Treatment Decision Aid for Women Aged 70 and Older

NCT02823262
View directory record Official record
Conditions
Breast Cancer, Estrogen Receptor Positive Breast Cancer, Node-negative Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Interventions
Breast Cancer Treatment Decision Aid for women 70+, Usual Care
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
70 Years and older · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 4, 2024 · Synced Sep 8, 2026, 6:01 PM EDT
Completed Phase 2 Interventional Results available

Clarification of Abatacept Effects in SLE With Integrated Biologic and Clinical Approaches

NCT02270957
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Abatacept, Placebo
Biological · Other
Lead sponsor
Oklahoma Medical Research Foundation
Other
Eligibility
18 Years to 70 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Sep 8, 2026, 6:01 PM EDT
Completed Phase 1Phase 2 Interventional

Adding New Drugs for HIV Infected Patients Failing Current Therapy

NCT00031044
View directory record Official record
Conditions
HIV Infections
Interventions
Enfuvirtide, Amdoxovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
8
States / cities
Denver, Colorado • Miami, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 8, 2026, 6:01 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin

NCT03066830
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Sotagliflozin (SAR439954), Placebo, Metformin, Sulfonylurea
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
28
States / cities
Litchfield Park, Arizona • Peoria, Arizona • Greenbrae, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Sep 8, 2026, 6:01 PM EDT
Completed No phase listed Observational Results available

BRAVO: Background Regimen of Raltegravir on Virologic Outcome

NCT00751530
View directory record Official record
Conditions
HIV Infections
Interventions
raltegravir
Drug
Lead sponsor
Community Research Initiative of New England
Other
Eligibility
16 Years and older
Enrollment
442 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Glastonbury, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 8, 2026, 6:01 PM EDT
Completed Not applicable Interventional

Guided Self-Help for Binge Eating Disorder

NCT01282736
View directory record Official record
Conditions
Binge Eating Disorder
Interventions
Integrative Response Therapy, Cognitive Behavioral Therapy
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Sep 8, 2026, 6:01 PM EDT
Completed Phase 3 Interventional Results available

A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes

NCT04596631
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Oral semaglutide, Placebo (semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
10 Years to 18 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
23
States / cities
Birmingham, Alabama • Los Angeles, California • New Haven, Connecticut + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 8, 2026, 6:01 PM EDT
Recruiting Phase 3 Interventional

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

NCT07225946
View directory record Official record
Conditions
Prostatic Neoplasms, Castration-Resistant
Interventions
Pasritamig, Docetaxel, Prednisone/Prednisolone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
53
States / cities
Chandler, Arizona • Little Rock, Arkansas • Fountain Valley, California + 46 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 8, 2026, 6:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Assessing the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interactions of PTI-801 in Healthy Volunteers, and Safety, Tolerability, and Pharmacokinetics of PTI-801 in Subjects With Cystic Fibrosis

NCT03140527
View directory record Official record
Conditions
Healthy Volunteer, Cystic Fibrosis
Interventions
PTI-801, Placebo, PTI-808
Drug
Lead sponsor
Proteostasis Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
33
States / cities
Birmingham, Alabama • Anchorage, Alaska • Stanford, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2020 · Synced Sep 8, 2026, 6:01 PM EDT
Completed Phase 1Phase 2 Interventional

Study Evaluating Multiple Doses Of ATN-103 In Subjects With Active Rheumatoid Arthritis

NCT00959036
View directory record Official record
Conditions
Active Rheumatoid Arthritis
Interventions
ATN-103, Placebo, Methotrexate
Drug
Lead sponsor
Ablynx, a Sanofi company
Industry
Eligibility
18 Years to 80 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
37
States / cities
Birmingham, Alabama • Huntsville, Alabama • Peoria, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2013 · Synced Sep 8, 2026, 6:01 PM EDT
Enrolling by invitation Phase 3 Interventional

An Extension Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

NCT05352919
View directory record Official record
Conditions
Systemic Lupus Erythematosus (SLE)
Interventions
Litifilimab, Litifilimab-matching placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
864 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
37
States / cities
Phoenix, Arizona • Beverly Hills, California • Huntington Beach, California + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 8, 2026, 6:01 PM EDT
Completed Not applicable Interventional

Opioid Counseling Following Orthopaedic Surgery

NCT04138264
View directory record Official record
Conditions
Orthopedic Disorder
Interventions
Preoperative opioid counseling
Other
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 23, 2019 · Synced Sep 8, 2026, 6:01 PM EDT